46% drop in opioid overdose deaths in Palm Beach County in 2024, medical examiner reports
BOCA RATON — Describing it as one of the most significant year-to-year drops Florida has seen, state and local officials announced a 46% drop in opioid overdose deaths in Palm Beach County last year compared to in 2023.
The county reported 224 confirmed opioid deaths in 2024, compared to 414 in 2023, according to statistics from the Palm Beach County Medical Examiner's Office. The office has not released a final total for 2024, as 13 cases from November and December are still under review.
But officials hosting a forum on the opioid epidemic Tuesday at Florida Atlantic University said the reported decline shows signs of progress.
"This is a historic drop in deaths," said Andrae Bailey, founder and CEO of the Orlando-based organization, Project Opioid, which hosted the forum. "It means that what the community is doing here is working. I think what's clear is the distribution of naloxone, along with community partners offering treatment for people who are struggling, it's working."
The Florida Shuffle: State's failure to oversee addiction treatment leaves patients in deadly danger
Former Palm Beach County commissioner Melissa McKinlay and former State Attorney Dave Aronberg were among those who spoke during the forum, discussing the county's efforts to stem the opioid crisis.
Aronberg, who ended his tenure as state attorney in January after serving three terms, reflected on his time in the office, including the formation of the county's Sober Homes Task Force nearly a decade ago to combat unscrupulous treatment facilities.
"We were able to make the progress we have accomplished by shutting the pill mills, passing state laws," he said. "By shutting down the drug treatment centers that were rogue. By shutting down the sober homes that were unscrupulous."
Aronberg said the number of emergency calls to Palm Beach County Fire Rescue for suspected overdoses has significantly declined since the task force was formed in 2016.
From the courts: Sober home owner's 'lies' earn new trial for doctor accused of millions in insurance fraud
When asked what solutions he would propose to fight the opioid crisis growing forward, Aronberg stressed the need for reforms at the federal level, in particular changes to the reimbursement model for treatment providers under the Affordable Care Act.
"I would change the Affordable Care Act from an old school fee-per-service reimbursement model, where the more services you provide, the more money you get paid, and I would change it to what have now for everything else within our health care system that Medicare pays for," he said.
"We have outcome-based reimbursement so the better hospitals with better results get paid more. … We've got to create some sort of mechanism to reward the good providers and punish the bad ones."
McKinlay said the decline in opioid deaths is encouraging, but stressed that the county and state continue to face challenges as newer illicit drugs become available.
She noted a significant jump in overdose deaths in the county nearly a decade ago. According to federal Centers for Disease Control & Prevention statistics dating to 2013, drug overdose deaths in Palm Beach County rose from 335 cases in 2015 to a peak of 636 cases in 2017.
"I'm not going to forget that graph that at one point showed that number in the low 300s, and what it did two years later, almost 650 people who lost their lives," McKinlay said.
"The drug dealers will find a new drug. That drug will be resistant to Narcan. We need to make sure that we have resources in place so we never see that 600-plus number again. "
Bailey said that while the number of overdose deaths has declined, drug overdoses in general have increased, a trend seen statewide.
"People are still struggling with drugs and alcohol at a historic rate," he said. "The mental health crisis is driving that. On one hand, we have to applaud the reduction in deaths. On the other hand, we have to realize that people are still struggling with drugs more than ever."
Julius Whigham II is a criminal justice and public safety reporter for The Palm Beach Post. You can reach him at jwhigham@pbpost.com and follow him on Twitter at @JuliusWhigham. Help support our work: Subscribe today.
This article originally appeared on Palm Beach Post: Opioid overdose deaths down sharply in Palm Beach County during 2024
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


American Military News
an hour ago
- American Military News
Judge approves $69M class action settlement in UnitedHealth 401(k) litigation
A federal judge in Minneapolis said Thursday he would approve a $69 million settlement in a class action lawsuit alleging UnitedHealth Group depressed the retirement savings of workers for years by selecting poorly performing investment options in the company 401(k) plan. The litigation alleged 'the fix was in' to retain investment funds managed by California-based Wells Fargo, in order to protect UnitedHealth Group's significant business relationship with the big bank, which was buying employee health insurance from the company's UnitedHealthcare division. Last year, Judge John Tunheim of the U.S. District Court of Minnesota said the case could move forward after determining 'a reasonable trier of fact could easily find' that Kim Snyder, the lead plaintiff in the case, caught the Eden Prairie-based company 'with its hand in the cookie jar.' UnitedHealth Group issued a statement Thursday that while it denied any allegation the company failed to act in the best interest of plan participants, 'this settlement allows all parties to put this matter behind them and move on.' The litigation unearthed a 2018 email in which Chief Financial Officer John Rex complained Wells Fargo was shifting its insurance business away from UnitedHealthcare, even though Rex had 'stepped in front of a freight train' to maintain Wells Fargo as the default retirement investment fund despite recommendations from an internal committee. Snyder knew none of this when she first brought the case, she said in an interview following Thursday's court hearing for final settlement approval. After losing her job about four years ago with the company's Optum division, Snyder reviewed her retirement savings, she said, and started questioning why the investments hadn't grown more. A Detroit resident, Snyder, 64, is a nurse who worked remotely for Optum's pharmacy business. 'I think they took the employees' wealth,' Snyder said. 'They took advantage of that, when [workers] were giving them money to invest … and used it for their own purposes. That was the freight train that nobody knew about.' Wells Fargo sold off its asset management business years ago. As of Thursday afternoon, Tunheim had not yet issued final paperwork cementing the settlement, but he said from the bench he would sign proposed orders drafted by attorneys without major changes. The draft called for lawyers to receive one-third of the settlement fund, or $23 million, plus reimbursement of $735,162 in costs. The rest will be distributed among hundreds of thousands of retirement plan holders. Snyder, as the sole class representative, would also receive a service award of $50,000. The $69 million settlement represents between 20% and 25% of likely potential recovery had plaintiffs prevailed in court, said Leigh Anne St Charles, a plaintiff attorney in Nashville who represented the class. Only two out of more than 350,000 class members filed letters of objection to the settlement. Both asked the court to consider an alternate age-weighted distribution formula for payouts, St. Charles said, even though age and length of service already are implied factors in settlement distributions. Each class member's proportional share will be based in part on the balance they invested in certain Wells Fargo Target Date Funds at any time since April 23, 2015, according to a website with settlement details. A settlement notice issued in the spring said class members don't need to do anything to receive payment. Current plan participants will receive their share in the form of a deposit into their plan accounts. Payments to former plan participants will be made directly by check unless they elect to receive funds via rollover to a qualified retirement account. Snyder first filed her lawsuit in 2021. In March 2024, Tunheim denied United's push for summary judgment in the case, citing evidence that Rex requested 'balance of trade' ledgers be produced showing how much business UnitedHealth Group conducted with Wells Fargo. On one side of the ledger, UnitedHealth generated between $50 million and $60 million in revenue over four years as health insurance provider for Wells Fargo. On the other side, Wells provided substantial banking services to UnitedHealth, which was the bank's 'largest client and lifeline' in the market for target-date funds, the judge wrote. The comparisons showed that, among the firms, UnitedHealth's most profitable relationship was with Wells Fargo. ___ © 2025 The Minnesota Star Tribune. Distributed by Tribune Content Agency, LLC.
Yahoo
an hour ago
- Yahoo
Debiopharm's ADC Research Gains Momentum With Launch of First-in-human Trial Assessing Debio 1562M in Acute Myeloid Leukemia Patients
First patient dosed with Debiopharm's first-in-class CD37 targeted antibody drug conjugate (ADC) in a Phase 1/2, multicenter, open-label trial, for patients with acute myeloid leukemia (AML) LAUSANNE, Switzerland, June 16, 2025--(BUSINESS WIRE)--Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed in the first-in-human clinical trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M monotherapy in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). This phase 1/2 trial (NCT06969430) will lay the groundwork for further development as it will allow the characterization of the safety and tolerability of the drug, dose optimization, and define the product's activity. AML remains a significant unmet need in oncology, particularly for older adults who account for the majority of cases. Despite advances in our understanding of AML biology and the introduction of new therapies, outcomes remain dismal for many patients—especially those who are not candidates for intensive treatments such as traditional chemotherapy or stem cell transplantation. While intensive chemotherapy and targeted therapies are available, they have not substantially improved long-term outcomes across all patient populations. The 5-year overall survival (OS) rate remains at just 32%1, with a median OS as low as 7 months in certain populations.2 This stark therapeutic gap leaves thousands of patients without viable treatment options each year, highlighting an urgent need for innovative interventions capable of extending survival. Transformative solutions are critical to improving both prognosis and quality of life for this underserved population within the AML treatment landscape. "It's time for AML research to advance with more precise therapeutic options," expressed Marianna Muller, Senior Medical Director, Oncology, Debiopharm. "This study will help us better understand the potential of Debio 1562M and how it could provide an effective new treatment while minimizing tolerability challenges for patients facing this very difficult disease with high unmet medical need." CD37, a cell-surface antigen, has been shown to be a relevant ADC target in AML due to its broad expression on blasts and leukemic stem cells along with efficient internalization.3 Research reveals that this increased expression is restricted to malignant cells compared to healthy hematopoietic stem cells and is correlated with poor patient outcomes.3 Debio 1562M is a next generation ADC targeting CD37 with 1st-in-class potential. The compound was designed using Debiopharm's Trifecta approach optimizing 3 key components: naratuximab - an anti-CD37 monoclonal antibody, Multilink™ proprietary linker technology, and a microtubule inhibitor as cytotoxic payload. In pre-clinical studies, Debio 1562M showed anti-leukemic activity across all AML subtypes as well as superior activity vs. the current standard-of-care and targeted therapies in AML models. Debiopharm has been involved in targeted drug delivery for more than a decade, developing MultiLink™—our unique and versatile proprietary ADC technology suite, key components of which are integrated into this product. We recognize how critical the need is for AML patients and remain dedicated to addressing it through our ADC expertise. As our pre-clinical results have shown promising antitumor activity and tolerability in this hard-to-treat leukemia, we're looking forward to seeing what this clinical stage research with Debio 1562M could reveal," mentioned Bertrand Ducrey, CEO of Debiopharm. Debiopharm's ADC Expertise We're developing fit-for-purpose antibody-drug conjugates (ADCs) through a tailored "Trifecta" approach: strategic target selection, innovative MultiLink™ linker technology, and smart payload choices. Our ADC portfolio includes first-in-class or best-in-class candidates: Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and Debio 0532, an HER3-targeted ADC for solid tumors, as well as other undisclosed targets. We are actively partnering to access innovative targets, co-develop, or out-license our ADC programs. Key partnerships include options to in-license bispecific antibodies targeting HER2-HER3 and HER3-EGFR. To enable both high drug-to-antibody ratios (DAR) and high stability, our ADCs are designed with our proprietary MultiLink™ linker technology. We have strong in-house capabilities and in-depth expertise spanning ADC conjugation and optimization, pharmacokinetics/pharmacodynamics (PK/PD), toxicology, translational, pharmaceutical (CMC) and clinical development, and supply chain management. We continue to invest in and explore potential game-changing technologies, such as novel and dual payloads. Debiopharm's Commitment to Patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit Follow us on LinkedIn @DebiopharmInternational Sources [1] National Cancer Institute. 2020. SEER Cancer Stat Facts: Acute Myeloid Leukemia. Available at: [2] Meyers J, et al. Applied health economics and health policy. 2013 11 (3): 275-286. [3] Lisa Ivanschitz, AACR 2025 Abstract # 1160 View source version on Contacts Debiopharm Contact Dawn BonineHead of Tel: +41 (0)21 321 01 11 Sign in to access your portfolio


Business Wire
2 hours ago
- Business Wire
Debiopharm's ADC Research Gains Momentum With Launch of First-in-human Trial Assessing Debio 1562M in Acute Myeloid Leukemia Patients
LAUSANNE, Switzerland--(BUSINESS WIRE)-- Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed in the first-in-human clinical trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M monotherapy in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). This phase 1/2 trial (NCT06969430) will lay the groundwork for further development as it will allow the characterization of the safety and tolerability of the drug, dose optimization, and define the product's activity. AML remains a significant unmet need in oncology, particularly for older adults who account for the majority of cases. Despite advances in our understanding of AML biology and the introduction of new therapies, outcomes remain dismal for many patients—especially those who are not candidates for intensive treatments such as traditional chemotherapy or stem cell transplantation. While intensive chemotherapy and targeted therapies are available, they have not substantially improved long-term outcomes across all patient populations. The 5-year overall survival (OS) rate remains at just 32% 1, with a median OS as low as 7 months in certain populations. 2 This stark therapeutic gap leaves thousands of patients without viable treatment options each year, highlighting an urgent need for innovative interventions capable of extending survival. Transformative solutions are critical to improving both prognosis and quality of life for this underserved population within the AML treatment landscape. 'It's time for AML research to advance with more precise therapeutic options,' expressed Marianna Muller, Senior Medical Director, Oncology, Debiopharm. 'This study will help us better understand the potential of Debio 1562M and how it could provide an effective new treatment while minimizing tolerability challenges for patients facing this very difficult disease with high unmet medical need.' CD37, a cell-surface antigen, has been shown to be a relevant ADC target in AML due to its broad expression on blasts and leukemic stem cells along with efficient internalization. 3 Research reveals that this increased expression is restricted to malignant cells compared to healthy hematopoietic stem cells and is correlated with poor patient outcomes. 3 Debio 1562M is a next generation ADC targeting CD37 with 1 st -in-class potential. The compound was designed using Debiopharm's Trifecta approach optimizing 3 key components: naratuximab - an anti-CD37 monoclonal antibody, Multilink™ proprietary linker technology, and a microtubule inhibitor as cytotoxic payload. In pre-clinical studies, Debio 1562M showed anti-leukemic activity across all AML subtypes as well as superior activity vs. the current standard-of-care and targeted therapies in AML models. Debiopharm has been involved in targeted drug delivery for more than a decade, developing MultiLink™—our unique and versatile proprietary ADC technology suite, key components of which are integrated into this product. We recognize how critical the need is for AML patients and remain dedicated to addressing it through our ADC expertise. As our pre-clinical results have shown promising antitumor activity and tolerability in this hard-to-treat leukemia, we're looking forward to seeing what this clinical stage research with Debio 1562M could reveal,' mentioned Bertrand Ducrey, CEO of Debiopharm. Debiopharm's ADC Expertise We're developing fit-for-purpose antibody-drug conjugates (ADCs) through a tailored 'Trifecta' approach: strategic target selection, innovative MultiLink™ linker technology, and smart payload choices. Our ADC portfolio includes first-in-class or best-in-class candidates: Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and Debio 0532, an HER3-targeted ADC for solid tumors, as well as other undisclosed targets. We are actively partnering to access innovative targets, co-develop, or out-license our ADC programs. Key partnerships include options to in-license bispecific antibodies targeting HER2-HER3 and HER3-EGFR. To enable both high drug-to-antibody ratios (DAR) and high stability, our ADCs are designed with our proprietary MultiLink™ linker technology. We have strong in-house capabilities and in-depth expertise spanning ADC conjugation and optimization, pharmacokinetics/pharmacodynamics (PK/PD), toxicology, translational, pharmaceutical (CMC) and clinical development, and supply chain management. We continue to invest in and explore potential game-changing technologies, such as novel and dual payloads. Debiopharm's Commitment to Patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit [1] National Cancer Institute. 2020. SEER Cancer Stat Facts: Acute Myeloid Leukemia. Available at: [2] Meyers J, et al. Applied health economics and health policy. 2013 11 (3): 275-286. [3] Lisa Ivanschitz, AACR 2025 Abstract # 1160